Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Trial ID or NCT#

NCT01020305

Status

not recruiting iconNOT RECRUITING

Purpose

This study evaluates if temsirolimus causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).

Official Title

Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology
Stefanie S. Jeffrey, MD

Contact us to find out if this trial is right for you.

Contact

Denise Haas
6507361252

View on ClinicalTrials.gov